Fox Foundation's Parkinson's initiative expands into Australia; Qiagen, Pfizer partner on molecular diagnostic test;

> The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative has expanded into Australia, where the foundation is currently recruting people to join the global study. Story

> A group of proteins called the Bcl-2 family could be markers to predict which patients will most benefit from a new drug to treat chronic leukemia. Story

> Germany's Qiagen is partnering with Pfizer to develop a companion molecular diagnostic test that would be used with an investigative Pfizer drug for non-small cell lung cancer. Financial terms were not disclosed. Release

> Quanterix, a Cambridge, MA-based company developing ultra-sensitive detection systems for use in research and in-vitro diagnostics, says its high sensitivity digital ELISA helped a pilot study identify inflammation biomarkers from patients with Crohn's disease. Quanterix release

> Biomarker patent application of the week: Novel groups of biomarkers for diagnosing Alzheimer's disease. Patent application

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.